## **2-Deoxy-2-iodo-***â***-glucopyranosyl Fluorides: Mild and Highly Stereoselective Glycosyl Donors for the Synthesis of 2-Deoxy-***â***-glycosides from** *â***-Hydroxy Ketones**

## **Nicolas Blanchard and William R. Roush\***

*Department of Chemistry, University of Michigan, 930 North University, Ann Arbor, Michigan 48109-1055.*

*roush@umich.edu*

**Received November 9, 2002**

## **ORGANIC LETTERS 2003 Vol. 5, No. 1 <sup>81</sup>**-**<sup>84</sup>**





**2-Deoxy-2-iodo-***â***-glucopyranosyl fluoride 14 is a highly stereoselective glucopyranosyl donor that may be activated under mild conditions. Application of this new glycosyl donor to the glycosidation reactions of a variety of acceptors including** *â***-hydroxy ketones affords** *â***-glycosides with high efficiency and stereoselectivity.**

2-Deoxy-glycosides are important structural units found in numerous natural and biologically active compounds such as the angucycline family of antibiotics (landomycin A), the aureolic acid antibiotics (olivomycin A, chromomycin  $A_3$ ), the enediynes (calicheamycin  $\gamma_1^I$ , esperamicins A<sub>1</sub> and C), the avermectins (avermectin  $B_{1a}$ , ivermectin), some cholestane glycosides  $(OSW-1)$ , and cardiac glycosides.<sup>1</sup> Although some general methods have been developed for the stereoselective construction of 2-deoxy- $\alpha$ -glycosidic linkages (mainly by electrophilic addition to glycals),<sup>2</sup> preparation of the corresponding  $\beta$ -linkage has proved to be much more difficult. Our group has been involved in the development of new methods of synthesis of this challenging 2-deoxy- $\beta$ -glycosidic linkage.<sup>3-5</sup> We previously reported that 2-deoxy2-iodo-*â*-glucopyranosyl acetates **<sup>1</sup>**<sup>4</sup> and 2-deoxy-2-iodo-Rglucopyranosyl trichloroacetimidates **2**<sup>5</sup> are highly reactive glycosyl donors for establishing *â*-linked glycosides. The  $C(2)$ -iodo unit can then be reductively removed<sup>6</sup> under mild

(4) Roush, W. R.; Bennett, C. E. *J. Am. Chem. Soc.* **1999**, *121*, 3541. (5) (a) Roush, W. R.; Chong, P. *Org. Lett*. **2002**, *4*, 4523. (b) Roush, W. R.; Gung, B. W.; Bennett, C. E. *Org. Lett.* **1999**, *1*, 891.

<sup>(1) (</sup>a) Albrecht, H. P. Cardiac Glycosides. In *Naturally Occurring Glycosides*; Ikan, R., Ed.; Wiley: Chichester, U.K., 1999; p 83. (b) Weymouth-Wilson, A. C. *Nat. Prod. Rep.* **1997**, *14*, 99.

<sup>(2) (</sup>a) Veyrières, A. Special Problems in Glycosidation Reactions: 2-Deoxy Sugars. In *Carbohydrates in Chemistry and Biology*; Ernst, B., Hart, G. W., Sinay, P., Eds.; Wiley-VCH: Weinheim, Germany, 2000; Part I, Vol. I, p 367. (b) Marzabadi, C. H.; Franck, R. W. *Tetrahedron* **2000**, *56*, 8385. (c) Kirshning, A.; Bechthold, A. F.-W.; Rohr, J. *Top. Curr. Chem.* **1997**, *188*, 1. (d) Danishefsky, S. J.; Bilodeau, M. T. *Angew. Chem., Int. Ed. Engl.* **<sup>1996</sup>**, *<sup>35</sup>*, 1380. (e) Toshima, K.; Tatsuta, K. *Chem. Re*V*.* **<sup>1993</sup>**, *93*, 1503.

<sup>(3)</sup> Leading references: (a) Roush, W. R.; Hartz, R. A.; Gustin, D. J. *J. Am. Chem. Soc.* **1999**, *121*, 1990. (b) Roush, W. R.; Sebesta, D. P.; Bennett, C. E. *Tetrahedron* **1997**, *53*, 8825, 8837. (c) Roush, W. R.; Briner, K.; Kesler, B. S.; Murphy, M.; Gustin, D. J. *J. Org. Chem*. **1996**, *61*, 6098.

<sup>(6)</sup> Miura, K.; Ichinose, Y.; Nozaki, K.; Fugami, K.; Oshima, K.; Utimoto, K. *Bull. Chem. Soc. Jpn*. **1989**, *62*, 143.



conditions, leading to the desired 2-deoxy- $\beta$ -glycosidic unit in high yield (Scheme 1).

During the course of our studies directed toward the total synthesis of formamicin (Figure 1),<sup>7</sup> a complex member of the plecomacrolide family of antibiotics, we anticipated the need to perform a *â*-selective glycosidation reaction of a latestage *â*-hydroxy ketone (aldol) intermediate. We report herein the results of our studies of this key glycosidation reaction using model substrates, which led to the development of a highly selective synthesis of 2-deoxy-*â*-glycosides using 2-deoxy-2-iodo-*â*-glycosyl fluorides as the glycosyl donors.



**Figure 1.** Formamicin and the targeted late stage  $\beta$ -hydroxy ketone (aldol) glycosidation substrate.

Although *â*-selective glycosidation reactions of *â*-hydroxy carbonyl compounds are known in the literature, 9,11,12 a general method proceeding in good yield and selectivity is

(11) Paterson, I.; McLeod, M. D. *Tetrahedron Lett*. **1995**, *36*, 9065.

(12) Evans, D. A.; Kaldor, S. W.; Jones, T. K.; Clardy, J.; Stout, T. J. *J. Am. Chem. Soc.* **1990**, *112*, 7001.

not yet available. An intrinsic limitation in the glycosidation of *â*-hydroxy ketones is the weakened reactivity of the acceptor, due to intramolecular hydrogen bonding of the hydroxyl hydrogen to the carbonyl moiety.8 Selected relevant examples of *â*-selective glycosidation reactions of aldol acceptors with 2-deoxy donors have been reported by Tastuta and Kinoshita.<sup>9</sup> Glycosidation of a  $\beta$ -hydroxy ketone with a 2-deoxy glycosyl fluoride under modified Mukaiyama's conditions10 proceeded in 30% yield and unreported anomeric selectivity. Upon reinvestigation of this reaction in connection with a total synthesis of concanamycin A, Paterson<sup>11</sup> obtained the glycoside product in only 12% yield and a  $\beta$ : $\alpha$  ratio of 1:1.4. After screening a variety of 2-deoxyglycosyl donors, Paterson determined that the 2-deoxy-glycosyl bromide was the most *â*-selective of those examined. The desired 2-deoxy- $\beta$ -glycoside was obtained with 2.5:1  $\beta$ : $\alpha$  selectivity in 21% yield.<sup>11</sup> In Evans' total synthesis of cytovaricin, $12$  the glycosidation of a *â*-hydroxy Weinreb amide derivative with a 2-deoxy glycosyl acetate using trityl perchlorate activation provided the  $\beta$ -glycoside product in 70% yield with a  $\beta$ :  $\alpha$ selectivity of 4:1. This glycosidation reaction was extremely sensitive to variation of protecting groups, solvents, and temperatures.

The lack of general methods available to efficiently glycosidate aldols in a *â*-selective manifold presented a unique opportunity to test our highly reactive and stereoselective 2-deoxy-2-iodo-glucopyranosyl acetate (**1)** and trichloroacetimidate (**2**) methodology.

Glycosidation reactions of *â*-hydroxy ketone **12** (corresponding to the C18-C24 fragment of formamicin) with 2-iodo-2-deoxy glycosyl acetates (**5**-**7**), imidates (**8**-**10**), or phosphate<sup>13</sup> 11 in the presence of a variety of promoters (TMSOTf,  $BF_3$ <sup>-</sup>OEt<sub>2</sub>,  $TrClO_4$ <sup>12</sup> K10 clay,<sup>14</sup> LiClO<sub>4</sub>,<sup>15</sup><br>LiOTf<sup>16</sup>) led only to decomposition of the acceptor (Scheme LiOTf<sup>16</sup>) led only to decomposition of the acceptor (Scheme 2). Control experiments showed that in the presence of 0.3 equiv of TMSOTf, the acceptor **12** was not stable for more than 20 min at low temperature ( $-78$  to  $-30$  °C). Optimization of the glycosidation with TBSOTf (0.3 equiv) as the promoter led to a disappointing 21% yield of the desired glycosylated product **13** but with excellent anomeric selectiv-



<sup>(7) (</sup>a) Igarashi, M.; Kinoshita, N.; Ikeda, T.; Nakagawa, E.; Hamada, M.; Takeuchi, T. *J. Antibiot.* **1997**, *50*, 926. (b) Igarashi, M.; Nakamura, H.; Naganawa, H.; Takeuchi, T. *J. Antibiot.* **1997**, *50*, 932. Correction: *J. Antibiot*. **1998**, *51*, C1.

<sup>(8)</sup> A similar hydrogen-bonding pattern has been reported to increase the nucleophilicity of hydrogen-bound hydroxyl acceptors: Mitchell, S. A.; Pratt, M. R.; Hruby, V. J.; Polt, R. *J. Org. Chem.* **2001**, *66*, 2327. However, our data indicate that hydrogen-bound aldols such as **12** and **16** are considerably less reactive than acceptors **19** and **21**.

<sup>(9)</sup> Toshima, K.; Misawa, M.; Ohta, K.; Tatsuta, K.; Kinoshita, M. *Tetrahedron Lett*. **1989**, *30*, 6417.

<sup>(10)</sup> Mukaiyama, T.; Murai, Y.; Shoda, S.-i. *Chem. Lett.* **1981**, 431.

ity  $(\beta:\alpha > 98: 2).^{17}$  This example further confirms that TBSOTf is superior to TMSOTf for the glycosidation reactions of sensitive substrates.2b,5,18 However, to achieve a synthetically useful glycosidation procedure with aldol acceptors, it was clear that almost neutral activation conditions of the donor would be required.19

We anticipated that a donor combining a C(2)-iodo substituent, which we have shown to be a very efficient  $\beta$ -directing group,<sup>4,5</sup> with an anomeric fluoride leaving group might help to circumvent the stability problems noted above. 2-Iodo-2-deoxy glycosyl fluorides were first reported by Wood et al. in 1966,<sup>20</sup> and have continued to be targets of methodological studies for the past 30 years.<sup>21</sup> However, only one report of glycosidation reactions involving this class of donor has been disclosed, in which cyclohexanol was used as the acceptor.22 Therefore, we decided to explore the potential of 2-iodo-2-deoxy-*â*-glycosyl fluorides in the glycosidation reactions of *â*-hydroxy ketones.

2-Iodo-2-deoxy-glycosyl fluorides are easily prepared in two steps starting from the corresponding 2-iodo-2-deoxy $β$ -glycosyl acetate (Scheme 3). For the present purposes, we



elected to use the readily accessible glycosyl acetate **5**<sup>4</sup> as starting material. Use of a substrate with a C(6)-bromo substituent simplifies the overall synthetic sequence, in that the  $C(2)$ -iodo and  $C(6)$ -bromo substituents can be reduced in the same step to give the targeted 2,6-dideoxy-*â*-glycosides (vide infra). Thus, cleavage of the anomeric acetate unit of **5** with hydrazine followed by transformation of the mixture

of hemiacetals to the glycosyl fluoride **14** by using DAST23 proceeded in 78% yield and excellent anomeric stereoselectivity ( $\beta$ : $\alpha$  > 98: 2). The configuration of the anomeric center was determined by measurement of the coupling constant  $(J_{1-2} = 8.4 \text{ Hz})^{17}$  after desilylation (HF $\cdot$ NEt<sub>3</sub>, CH<sub>3</sub>CN, 60) °C).24 Donor **14** is relatively stable and could be stored at  $-20$  °C for more than two weeks without any noticeable decomposition.

With the glycosyl donor **14** in hand, we turned our attention toward the glycosidation reaction of the  $\beta$ -hydroxy ketone **12**. To our delight, slow addition of donor **14** to a solution of  $\beta$ -hydroxy ketone 12, stannous chloride, and silver perchlorate in diethyl ether at  $-15$  °C according to Mukaiyama's general procedure<sup>10</sup> provided the coupled product 13 in 65% yield with excellent stereoselectivity  $(\beta:\alpha)$ <sup>&</sup>gt; *<sup>9</sup>*8: 2)17 (Scheme 4). Silver triflate proved equally effective



as the activating agent (58% isolated yield of **13**) whereas addition of a base  $(2,6$ -lutidine)<sup>25</sup> led to a lower yield  $(24%)$ . Other promoters  $(AgClO_4/Cp_2HfCl_2,^{26} AgClO_4/Cp_2ZrCl_2,^{27}$  $AgSbF<sub>6</sub>/SnCl<sub>2</sub>$ ) or incorporation of a more labile protecting group on the aldol acceptor (TES instead of TBS ether) resulted in unsuccessful glycosidation reactions. More elaborated  $\beta$ -hydroxy ketones (e.g., **16**) can also be glycosylated with the 2-iodo-2-deoxy-*â*-glycosyl fluoride **14** in very good yield and selectivity (84%,  $\beta$ : $\alpha$  > 98: 2).<sup>17</sup> Reductive removal of the C(2)-iodo and the C(6)-bromo substituents under mild conditions6 led to the desired 2-deoxy-glycoside units **15** and **18** in 72% and 90%, respectively.

<sup>(13)</sup> Lee, J.; Coward, J. K. *J. Org. Chem.* **1992**, *57*, 4126.

<sup>(14)</sup> Nagai, H.; Matsumura, S.; Toshima, K. *Tetrahedron Lett*. **2002**, *43*, 847.

<sup>(15)</sup> Waldmann, H.; Böhm, G.; Schmid, U.; Röttele, H. Angew. Chem., *Int. Ed. Engl.* **1994**, *33*, 1944.

<sup>(16)</sup> Lubineau, A.; Drouillat, B. *J. Carbohydr. Chem.* **1997**, *16*, 1179. (17) Determined by 500-MHz 1H NMR analysis of the crude reaction mixture.

<sup>(18)</sup> Roush, W. R.; Narayan, S. *Org. Lett.* **1999**, *1*, 899.

<sup>(19)</sup> Activation of a glycal donor in the presence of **12** was also attempted, but none of the literature methods examined (e.g., PPh<sub>3</sub>'HBr, NBS) led to formation of the  $\beta$ -glycoside product. The acceptor was recovered in these cases. *PPh<sub>3</sub>*'*HBr activation*: Bolitt, V.; Mioskowski, C.; Lee, S.-G.; Falck, J. R. J. Org. Chem. **1990**, 55, 5812. *NBS activation*: C.; Lee, S.-G.; Falck, J. R. *J. Org. Chem.* **1990**, 55, 5812. *NBS activation:* Toshima, K.; Tatsuta, K.; Kinoshita, M. *Bull. Chem. Soc. Jpn.* **1988**, 61, 2369.

<sup>(20)</sup> Wood, K. R.; Kent, P. W.; Fisher, D. *J. Chem. Soc. (C)* **1966**, 912. (21) (a) Evans, R. D.; Schauble, J. H. *Synthesis* **1987**, 551. (b) Campbell, J. C.; Dwek, R. A.; Kent, P. W.; Prout, C. K. *Carbohydr. Res.* **1969**, *10*, 71. (c) Hall, L. D.; Manville, J. F. *Can. J. Chem*. **1969**, *47*, 361. (d) Hall, L. D.; Manville, J. F*. Carbohydr. Res*. **1968**, *8*, 295. (e) Hall, L. D.; Manville, J. F. *Chem. Commun*. **1968**, *35*, 37.

<sup>(22)</sup> Nishimura, S.; Washitani, K. (Sumitomo Pharmaceuticals Co., Ltd., Japan), Stereoselective Production of Glycosyl Compound, Japanese Patent 09241288, 1997.

<sup>(23) (</sup>a) Rosenbrook, Wm., Jr.; Riley, D. A.; Lartey, P. A. *Tetrahedron Lett*. **1985**, *26*, 3. (b) Posner, G. H.; Haines, S. R. *Tetrahedron Lett*. **1985**, *26*, 5.

<sup>(24)</sup> Determination of the anomeric configuration of **14** by measurement of the  $J_{1,2}$  coupling constant was not possible since this donor exists in a twist-boat conformation to relieve the gauche interactions between the two bulky silyl ethers at C3 and C4.

<sup>(25)</sup> Nicolaou, K. C.; Caulfield, T.; Kataoka, H.; Kumazawa, T. *J. Am. Chem. Soc.* **1988**, *110*, 7910.

<sup>(26)</sup> Suzuki, K.; Maeta, H.; Matsumoto, T.; Tsuchihashi, G.-i. *Tetrahedron Lett*. **1988**, *29*, 3571.

<sup>(27)</sup> Matsumoto, T.; Maeta, H.; Suzuki, K.; Tsuchihashi, G.-i. *Tetrahedron Lett*. **1988**, *29*, 3567.

To test the scope of this glycosylation procedure, we subjected a variety of acceptors to glycosidation reactions with **14**. The results are presented in Scheme 5.



We have previously shown that the primary and secondary alcohols **19** and **21** are glycosylated in high yields and  $\beta$ -selectivities with donors such as **5**, under TMSOTf activation.4 The 2-iodo-2-deoxy-*â*-glycosyl fluoride **14** proved equally effective, with even greater selectivity in the case of the acceptor 21 ( $\beta$ : $\alpha$  > 98: 2 compared to  $\beta$ : $\alpha$   $\geq$  90:10 for the experiment with **5**<sup>4</sup> ). Acid-sensitive acceptors such as 23 are not stable above  $-50$  °C in the presence of a strong Lewis acid such as TMSOTf.<sup>18</sup> Consequently, the glycosidation of **23** in the presence of catalytic amounts of TMSOTf with the 2-iodo-2-deoxy-*â*-glycosyl acetate **5** proceeds in less than 11% yield  $(\beta:\alpha > 98: 2).^{28}$  Donor 14, however, undergoes this challenging glycosidation and permits disaccharide **24** to be obtained in 89% yield, the  $\beta$ -anomer being the only detectable diastereomer in this reaction.<sup>17</sup> Increasing the sensitivity of the acceptor as in the case of **25** led to several products, the major arising from Ferrier rearrangement.29 The rearranged coupled product **26** was isolated in 40% yield.

It is interesting to note that the conditions for activation of donors **1**, **2**, and **14** can be controlled such that it should be possible to use 6-heteroatom-substituted 2-iodo-glycosyl acetates or 2-iodo-glycosyl fluorides as acceptors in glycosidation reactions with 2-iodo-glycosyl trichloroacetimidates as the donors. The differential reactivity of these three classes of glycosyl donors should be of considerable utility in the synthesis of oligosaccharides containing 2-deoxyglycoside units.

In summary, we have shown that 2-iodo-2-deoxy-*â*glycosyl fluoride **14** is a synthetically useful glycosyl donor for establishing *â*-glycosidic linkages with a variety of acceptors. In particular, donor **14** gave excellent results in the glycosidation reaction of aldol acceptors **12** and **16**. Application of this methodology to the total synthesis of formamicin is currently underway and will be reported in due course.

**Acknowledgment.** We thank the National Institutes of Health (GM 38436) for support of this research. N.B. also acknowledges the Ministère Français des Affaires Etrangères for a Lavoisier Fellowship. We also thank Dr. Brad Savall for initial studies of the glycosidation reactions of aldol acceptors.

**Supporting Information Available:** Experimental procedures and spectral data for compounds **<sup>12</sup>**-**18**, **<sup>24</sup>**, and **26**. This material is available free of charge via the Internet at http://pubs.acs.org.

## OL027257H

<sup>(28)</sup> Bennett, C. E. Ph.D. Thesis, Indiana University, Bloomington, IN, 2000.

<sup>(29)</sup> We suspect that **26** arises via Ferrier-type decomposition of **25** to give an equivalent of Lewis acid complexed benzyloxide, which then undergoes standard Ferrier substitution with the cation generated from **25**. The resulting 3,4-unsaturated sugar then presumably undergoes subsequent, slower, glycosidation with **14** to give the observed product, **26**. It is of course conceivable that the order of these steps could be reversed. For additional examples of this process, see ref 28.